Results

Total Results: 4,696 records

Showing results for "1(SELECT 0 FROM (SELECT SLEEP(29))qsqli_3333) /*'XOR (SELECT 0 FROM (SELECT SLEEP(29))qsqli_3333); -- OR'|"XOR (SELECT 0 FROM (SELECT SLEEP(29))qsqli_3333); -- OR"*/".

81. Methods Guide for Comparative Effectiveness Reviews - Expanded Guidance on Selected Quantitative Synthesis Topics (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/quantitative-synthesis-expanded-methods_methods.pdf
    March 01, 2013 - needs to be considered. 4 Combining Composite Outcomes A composite outcome can be binary (0/ … control rate to rule out presence of a control rate effect; if the slope is significantly different than 0, … A RD of 2 percent could be clinically significant if the change is from 3 percent to 1 percent of an … Provide interpretation for results from test and exploration of heterogeneity. … Numbers needed to treat derived from meta-analyses— sometimes informative, usually misleading.

82. Slide 1
    effectivehealthcare.ahrq.gov/sites/default/files/comparator-selection-in-observational-chapter-5.pptx
    January 01, 2013 - Discuss potential bias (and methods to minimize it) associated with comparator choice Define time 0 … Defining time 0 for all comparator groups in describing planned analyses is also important. … One issue with no-treatment comparison groups is how to identify time 0. … It also prevents bias from arising from prevalent users being long-term adherers who may also follow … Time from disease onset to a treatment: Pay careful attention to the time from initial diagnosis and

83. Covariate Selection for Observational Comparative Effectiveness Research
    effectivehealthcare.ahrq.gov/sites/default/files/considerations-for-statistical-chapter-10.pptx
    January 01, 2013 - This presentation covers strategies for data analysis from simple descriptive statistics to more complex … Variables that are potentially on the pathway from treatment to outcome are not controlled for, because … Estimating causal effects from epidemiological data. … Like the propensity score, it is a summary measure derived from the observed values of the covariates … If subjects with missing data differ from subjects with complete data, then exposure estimates may be

84. Layout 1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/ischemic-stroke-treatment_executive.pdf
    January 01, 2011 - from 15 to 114 patients. … Penumbra System (numbers ranged from 15 to 125 patients). … Mean/median time from stroke symptom to either angiography or device deployment ranged from 141 to 388 … Consequently, the use of IV rtPA among studies ranged from 0 to 100 percent. … 0 1 0 0 Patients 371 0 31 211 173 12 12 0 53 14 0 0 34 0 0 BI Studies 1 0 0 1 0 0 Patients 5 0 0

85. Cannabis-2022-Update-Surv-Rep-1-App-F1-4 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2022-update-surv-rep-1-app-F1-4.xlsx
    January 01, 2022 - C, Δ 95% CI Upper Limit Intervention D, N Analyzed for Mean Δ From Baseline Intervention D, Mean Δ From … 16 0 0 16 0 0 16 0 0 16 0 6 16 37.5 0 16 0 6 16 37.5 1 16 6.25 7 16 43.75 0 16 0 NR NR NR NR NR NR NR … 5 0 1 7 14.29 0 5 0 0 7 0 0 5 0 4 7 57.14 3 5 60 NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR … 34 0 0 32 0 2 34 5.88 0 32 0 18 34 52.94 5 32 15.63 3 34 8.824 2 32 6.25 3 34 8.82 0 32 0 NR NR NR NR … Placebo cream, max 4 applications/day NA NA 4 Short 0 15 0 0 14 0 0 15 0 0 14 0 NR NR NR NR NR NR NR

86. Cannabis Article Selected as Best of 2022 | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/news/best-of-2022

87. Masks-Surveillance-2-Appendix-Table-A-1 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/masks-surveillance-2-appendix-table-a-1.xlsx
    April 09, 2020 - vs. 2% vs. 2% 1 adult influenza vaccinated: 0% vs. 4% vs. 4% A vs. … (0/92) B: 0% (0/94) C: 1% (1/100) Not reported Not reported A vs. … a randomly obtained swab from an asymptomatic participant; or influenza seroconversion (symptomatic … member (mean not reported) A. 19% age 0-15; 20% age 16-30; 50% age 31-50; 11% age ≥51 B. 16% age 0-15 … vs. 0% vs. 0% Household contacts Vaccination at least 14 days prior to index case symptom onset: 3%

88. Masks-Appendix-Table-B-1-Surveillance-Report (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/Masks-appendix-table-b-1-surveillance-report.xlsx
    April 09, 2020 - vs. 2% vs. 2% 1 adult influenza vaccinated: 0% vs. 4% vs. 4% A vs. … (0/92) B: 0% (0/94) C: 1% (1/100) Not reported Not reported A vs. … a randomly obtained swab from an asymptomatic participant; or influenza seroconversion (symptomatic … member (mean not reported) A. 19% age 0-15; 20% age 16-30; 50% age 31-50; 11% age ≥51 B. 16% age 0-15 … vs. 0% vs. 0% Household contacts Vaccination at least 14 days prior to index case symptom onset: 3%

89. Disposition of Comments for Technical Brief 29 Women Living With HIV-AIDS (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/women-hiv_disposition-comments.pdf
    November 21, 2016 - Lives of Women Aged 40 and Above Living With HIV/AIDS Draft review available for public comment from … The findings from the limited available literature were clearly stated. … We have expanded the Next Steps section with input from this reviewer and others. … Upon closer examination of the data it can be argued that forty-eight women died from AIDS from 1980 … the social worker or if the text is the interpretation/summary from the investigators.

90. Masks-Appendix-Table-B-1-Version-2 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/masks-appendix-table-b-1-version-2.xlsx
    April 09, 2020 - vs. 2% vs. 2% 1 adult influenza vaccinated: 0% vs. 4% vs. 4% A vs. … (0/92) B: 0% (0/94) C: 1% (1/100) Not reported Not reported A vs. … a randomly obtained swab from an asymptomatic participant; or influenza seroconversion (symptomatic … member (mean not reported) A. 19% age 0-15; 20% age 16-30; 50% age 31-50; 11% age ≥51 B. 16% age 0-15 … vs. 0% vs. 0% Household contacts Vaccination at least 14 days prior to index case symptom onset: 3%

91. Diagnosis and Management of Febrile Infants (0–3 Months) | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/febrile-infants-diagnosis-management/research
    March 27, 2012 - 2011 Topic Initiated Mar. 27, 2012 Systematic Review Diagnosis and Management of Febrile Infants (0– … followup for return visits/reassessment of infants after initial examination across four studies ranged from

92. App-E-Surv-Rept-1-Acute-Pain (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-e-surv-rept-1-acute-pain.xlsx
    September 21, 2022 - B Pain intensity (mean [99% CI] 0 to 10 NRS, estimated from figure): 4.2 (3.7 to 4.8) vs. 5.1 (4.5 to … B Roland Morris Disability Questionnaire (mean [99% CI] 0 to 24, estimated from figure): 15 (14 to 16 … -1.7 to 0.0) Pain improvement from baseline to 2 hours (mean [SD], 0 to 10 VAS): 4.0 (2.6) vs. 2.9 ( … B Pain intensity (mean [SD NR], 0 to 10 VAS, estimated from figure): 2.6 vs. 3.2 at 4 hours, 3.1 vs. … C or D Pain intensity difference (least mean square [SD NR], 0 to 10 NRS, estimated from graph): 5.2

93. Dia 1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/ijzerman_ahrq-webinar-mcda.pdf
    January 01, 2011 - AHP) CA methods Adapted from Mulye et al, J. Beh.Dec. … in case of anti-depressants 15 How patients and experts value patient relevant endpoints 0

94. Cer-250-Cannabis-Tables-F1-F2-2022-Update 0 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-tables-f1-f2-2022-update_0.xlsx
    January 01, 2022 - Table F-1. ROB RCTs Table F-1. Risk of bias of cannabis RCTs Author, Year Randomization Adequate? Allocation Concealment Adequate? Groups Similar at Baseline? Patient Masked? Care Provider Masked? Outcome Assessors Masked? Intention-To-Treat Analysis? Rate of Overall Attrition Within Acceptable Levels? Rate of Diffe…

95. Layout 1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/recombinant-factor-viia_executive.pdf
    May 01, 2010 - These uses differ substantially from the drug’s FDA approved label. … 08 -0 .2 2 0. 04 -0 .1 1 0. 44 -0 .5 3 4- 79 ex pa ns io n U C : U C : U C : U C : In … 07 -0 .3 1 0. 03 -0 .1 2 0. 02 -0 .0 6 6. 9- 16 .0 • H ad a n un cl ea r im pa ct … 0. 51 0- 0. 08 0. 04 -0 .1 6 7. 7- 14 .0 po te nt ia l f or b en ef it an d lit tle … U C : U C : U C : 0. 11 -0 .5 3 0. 08 -0 .1 8 10 .4 K Q 4 a .

96. Cannabis-2023-Surv-Rep-4-Tables-E-1-E-4 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2023-surv-rep-4-tables-E-1-E-4.xlsx
    January 01, 2023 - graph) NR NR NR 6 -0.2 (estimated from graph) NR NR NR 10 0 (estimated from graph) NR NR NR NA NA NA … 16 0 0 16 0 NA NA NA NA NA NA 0 16 0 0 16 0 NA NA NA NA NA NA 6 16 37.5 0 16 0 NA NA NA NA NA NA 6 16 … 5 0 NA NA NA NA NA NA 1 7 14.29 0 5 0 NA NA NA NA NA NA 0 7 0 0 5 0 NA NA NA NA NA NA 4 7 57.14 3 5 60 … Placebo cream, max 4 applications/day NA NA 4 Short 0 15 0 0 14 0 NA NA NA NA NA NA 0 15 0 0 14 0 NA … Placebo 8 Short NR NR NR NR NR NR NR NR NR NR NR NR 0 28 0 0 27 0 1 30 3.33 0 30 0 1 28 3.57 2 27 7.41

97. Microsoft Word - FORMATTED_A_process_for_robust_and_transparent_Methods_Paper_CH_10-7-11_Tufts_MB_10-27-11si[1].docx (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/quality-rating_research.pdf
    November 01, 2011 - Proportions of disagreements ranged from 0 percent (unanimous agreement among the reviewers in all studies … 0% 0% 9% 64% 55% 45% 0% 18% 27% 27% 9% 27% 18% 0% 27% 45% 0% 18% 0% 20% 40% 60% 80% … 0% 0% 46% 69% 8% 0% 0% 0% 92% 69% 69% 38% 100% 85% 100% 5% 10% 95% 65% 45% 0% 20% … 36% 9% 73% 0% 0% 9% 9% 9% 0% 18% 0% 27% 18% 45% 0% 9% 0% 73% 27% 0% 27% 0% 73% … Disagreements among reviewers ranged from 0 to 100 percent, indicating variable subjectivity across

98. Restless-Legs Research-Protocol (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/restless-legs_research-protocol.pdf
    December 16, 2011 - severity of disease and its impact  Scale with 10 items with each item rated on a 5 point scale (0 … symptoms)  Scores are combined to give a global assessment (0: No RLS; 1-10: mild; 11-20: moderate … Severity Rating Scale  ASRS, developed by the European RLS Study Group  A total score (range 0 … to 24) is  3 items (9 point: 0 = no sign of augmentation, 8 = signs of severe augmentation) are … will set responder criteria on these scale scores to be: 1) resolution of symptoms (IRLS scale score=0)

99. Emergency Medical Service/911 Workforce Mental or Behaviorial Health Issues (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/ems-911-workforce-topic-development-brief.pdf
    February 01, 2022 - -94 Total number of identified systematic reviews: 0 • AHRQ EPC: 0 • Cochrane: 0 • VA ESP: 0 • … PubMed: 0 • PsycInfo: 0 Primary articles: 0 1b and 2: Interventions addressing behavioral health … • Recruiting: 0 • Active: 0 • Complete: 0 Total number of identified systematic reviews: 1 • AHRQ … EPC: 0 • Cochrane: 0 • VA ESP: 0 • PubMed: 115 • PsycInfo: 0 Primary articles: 10136-145 … Clinicaltrials.gov • Recruiting: 0 • Active: 0 • Complete: 0 AHRQ=Agency for Healthcare Research

100. Version-3-Immunity-After-Covid-19-Appendix-Table-B-1 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/version-3-immunity-after-COVID-19-appendix-table-B-1.xlsx
     January 24, 2022 - Mild: Asthma/seasonal allergies: 6 (31.6) Diabetes: 2 (10.5) Hypertension: 5 (26.3) Cardiovascular: 0( … Caucasian: 31 (88.6) African: 3 (8.6) Asian: 1 (2.9) Immunocompetent Caucasian: 34 (97.1) African: 0 … (0) CVD: 4* (7.5) Asthma:4* (5.7) CKD stage 4 or 5: 0 (0) Anti-S RBD Architect SARS-CoV-2 IgG Quant Antibody … infection 0-7 days 10-28 days 6 to 10 weeks 6 to 12 months From participants included for serological … SARS-CoV-2 infection were collected from the SmiNet register.